查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016883

經導管栓塞和閉塞裝置市場：按產品類型、材料、技術、應用和最終用戶分類的全球市場預測，2026-2032年

Transcatheter Embolization & Occlusion Device Market by Product Type, Material, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，經導管栓塞和閉塞裝置市場價值將達到 58.9 億美元，到 2026 年將成長至 63.3 億美元，到 2032 年將達到 103.3 億美元，複合年成長率為 8.34%。

主要市場統計數據
基準年 2025 58.9億美元
預計年份：2026年 63.3億美元
預測年份 2032 103.3億美元
複合年成長率 (%) 8.34%

策略性地引入經導管栓塞/閉塞裝置，使其成為微創血管治療發展的關鍵驅動力。

經導管栓塞和閉塞裝置結合了先進的材料科學和精準的輸送系統，已成為微創血管治療轉型過程中不可或缺的基礎工具。這些裝置旨在阻斷各種臨床適應症中的病理性血流，並與介入放射學、血管外科和血管內神經外科的工作流程緊密結合。該領域的特點是臨床上對兼具療效、輸送精準性和可預測生物相容性的裝置的需求日益成長。隨著臨床醫師越來越重視縮短門診時間和手術時間，裝置設計者正積極研發創新技術，以簡化操作、提高影像清晰度並增強部署過程中的控制。

生物材料、輸送系統和手術流程的最新進展正在從根本上改變栓塞術的臨床實踐和商業策略。

栓塞和閉塞裝置領域正經歷著變革性的轉變，這主要得益於生物材料、輸送系統和手術技術的進步。材料科學的突破性進展催生了新一代液體栓塞劑和微球，這些栓塞劑和微球具有更可預測的聚合特性、更強的滲透性和可調控的吸收特性，從而拓展了治療選擇並提高了安全性。同時，包括血管栓塞器和可移除彈簧圈在內的機械閉塞技術也在不斷改進，以平衡血栓形成和血管保護，從而為各種不同的解剖結構挑戰提供量身定做的解決方案。

對不斷變化的貿易政策如何重塑栓塞器械利害關係人的採購、製造決策和市場進入進行全面評估。

美國近期加徵的關稅令全球醫療設備供應鏈更加複雜，對製造商、經銷商和醫療保健系統產生了連鎖反應。這些關稅改變了零件採購和成品進口的成本計算方式，可能促使企業進行策略調整，例如改變組裝流程、選擇替代供應商或加強垂直整合，以維持獲利能力和前置作業時間的連續性。對於依賴跨境採購特殊聚合物、金屬、微導管組件和成像標記的企業而言，由於供應商需要重新考慮運輸路線和庫存策略，這些政策變化可能導致交貨週期延長。

一項實用的細分分析，展示了產品類型、材料和技術如何與臨床用例和醫療保健環境相互作用，以及這些因素如何影響產品的採用。

詳細的細分分析揭示了不同產品類型、材料、技術、臨床應用和醫療環境中的性能促進因素和應用障礙，這些因素決定了製造商和醫療系統的策略重點。在產品類型中，栓塞彈簧圈（有可脫卸式和推入式兩種配置）仍然是靶向機械閉塞的關鍵，因為其放置精度至關重要。同時，液體栓塞劑（包括乙烯 - 乙烯醇和N-丁基氰基丙烯酸酯配方）為複雜的血管床提供了高度靈活的選擇。微球和顆粒栓塞劑可實現精確閉塞並具有可預測的遠端滲透性，而血管栓塞器則可在特定解剖結構中實現快速近端閉塞。每種產品組都有其獨特的操作特性、影像可見度以及操作者熟練度曲線，這些都會影響其在臨床路徑中的應用。

富有洞察力的區域觀點突顯了主要區域在監管、報銷和臨床引入方面的差異如何影響戰略市場方法。

區域趨勢對臨床實務模式、報銷架構和供應鏈結構有顯著影響，導致各大區域的優先事項有所不同。在美洲，臨床醫生通常優先考慮快速完成治療和便於門診就診的解決方案，因此，能夠提高工作流程效率和提供全面培訓支援的醫療器材備受關注。該地區的監管路徑和支付方結構促使製造商證明其產品的臨床療效和經濟價值，從而影響實證策略和商業性通訊。

檢驗了競爭動態、產品創新、證據產生和通路策略如何決定醫療設備製造商的市場定位。

栓塞和閉塞器材領域的競爭動態由產品創新、臨床證據、服務交付和通路關係等因素共同塑造。主要企業透過對下一代材料、改進劑量方案和增強與影像診斷的兼容性進行針對性投資來脫穎而出，同時優先考慮臨床醫生培訓和治療結果追蹤。器械製造商與學術機構和臨床網路之間的夥伴關係對於產生高品質的真實世界證據以及與介入團隊建立長期信任關係變得日益重要。

為製造商提供可操作且優先考慮的建議，以協調產品創新、臨床證據和商業性成功，從而加速產品推廣。

產業領導企業應推動一系列合作舉措，協調產品開發、臨床證據目標和商業性執行，以實現栓塞治療的長期價值。優先考慮模組化設計以及與常用微導管平台的兼容性，以減少手術操作的阻力，並擴大其在多種適應症中的臨床應用範圍。投資研發差異化的生物材料和成像標記物，以改善藥物傳輸控制和視覺化效果。這些技術差異化可以透過結構完善的研究和註冊登記轉化為可證實的臨床效益。

採用透明的混合方法研究途徑，結合臨床證據審查、專家訪談和同行檢驗，以確保獲得可靠且實用的見解。

本研究整合了同儕審查的臨床文獻、醫療設備監管申報文件、衛生監管機構的指導文件、對介入醫師和採購經理的訪談，以及對製造商技術規範的系統性回顧，旨在全面了解栓塞和閉塞器。資料收集強調可重複性和資訊來源三角驗證，將關鍵意見領袖（KOL）的定性見解與從公開的監管申報文件和醫師主導的註冊研究中提取的器械性能特徵相結合。受訪者的選擇涵蓋了不同的臨床專科、臨床環境和地理區域，以全面了解有關手術選擇和應用的考量。

整合各項結論，重點闡述決定哪些技術將被廣泛採用的臨床、營運和策略要求。

經導管栓塞和閉塞裝置處於臨床需求、材料創新和系統層面經濟考量交會的戰略要地。定義該領域的技術日趨成熟，這要求製造商在拓展臨床應用範圍的同時，也要在不同的醫療環境中展現出可驗證的價值。商業化的成功取決於能否平衡產品性能與實際應用因素，例如培訓、影像相容性和供應鏈韌性。此外，貿易和政策的變化凸顯了敏捷的生產和採購計畫的重要性，即使面臨外部衝擊，也能確保器械供應。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 經導管栓塞及閉塞裝置市場：依產品類型分類

  • 栓塞線圈
    • 可拆卸線圈
    • 推式線圈
  • 液態栓塞劑
    • 乙烯-乙烯醇共聚物
    • N-丁基氰基丙烯酸酯
  • 微球
  • 顆粒栓子
  • 血管栓塞

第9章 經導管栓塞及閉塞裝置市場：依材料分類

  • 生物基材料
  • 合成材料

第10章：經導管栓塞及閉塞裝置市場：依技術分類

  • 血流導栓塞術
  • 機械性閉塞
  • 微導管輸送系統

第11章 經導管栓塞與閉塞裝置市場：依應用分類

  • 出血控制
  • 肝動脈栓塞術
  • 神經血管栓塞術
  • 周邊血管栓塞
  • 子宮肌瘤栓塞術

第12章 經導管栓塞和閉塞裝置市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第13章 經導管栓塞及閉塞裝置市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 經導管栓塞及閉塞裝置市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 經導管栓塞和閉塞裝置市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國經導管栓塞、閉塞裝置市場

第17章：中國經導管栓塞和閉塞裝置市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AngioDynamics, Inc.
  • B. Braun Melsungen AG
  • Boston Scientific Corporation
  • Cook Medical LLC
  • Edwards Lifesciences Corporation
  • Johnson & Johnson
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Penumbra, Inc.
  • Terumo Corporation
  • WL Gore & Associates, Inc.
Product Code: MRR-03168519576B

The Transcatheter Embolization & Occlusion Device Market was valued at USD 5.89 billion in 2025 and is projected to grow to USD 6.33 billion in 2026, with a CAGR of 8.34%, reaching USD 10.33 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.89 billion
Estimated Year [2026] USD 6.33 billion
Forecast Year [2032] USD 10.33 billion
CAGR (%) 8.34%

A strategic introduction framing transcatheter embolization and occlusion devices as pivotal drivers of minimally invasive vascular therapy evolution

Transcatheter embolization and occlusion devices have emerged as foundational tools within the broader shift toward less invasive vascular therapies, integrating advanced materials science with precision delivery systems. These devices are engineered to occlude pathological blood flow across a diverse set of clinical indications, and they intersect with interventional radiology, vascular surgery, and endovascular neurosurgery workflows. The landscape is characterized by escalating clinical demand for options that combine efficacy, delivery accuracy, and predictable biocompatibility. As clinicians increasingly prioritize outpatient pathways and shorter procedural times, device designers are responding with innovations that streamline handling, enhance visibility under imaging, and improve controllability during deployment.

The evolution of device form factors has expanded therapeutic reach beyond traditional applications such as hemorrhage control and uterine fibroid embolization to embrace hepatic, peripheral vascular, and neurovascular interventions. Concurrently, procedural teams are integrating microcatheter technologies and hybrid delivery strategies to navigate complex anatomy and achieve durable occlusion. Regulatory authorities continue to refine pathways for minimally invasive solutions, prompting manufacturers to address both clinical evidence generation and post-market surveillance. Taken together, these forces are reshaping clinical algorithms and commercial models, demanding closer alignment among R&D, clinical affairs, and market access functions to ensure that new products deliver measurable improvements in patient outcomes and operational efficiency.

How recent advances in biomaterials, delivery systems, and procedural workflows are fundamentally reshaping clinical practice and commercial strategies in embolization

The landscape for embolization and occlusion devices is in the midst of transformative shifts driven by converging advances in biomaterials, delivery systems, and procedural practice. Material science breakthroughs are enabling next-generation liquid embolics and microspheres that offer more predictable polymerization, enhanced radiopacity, and tunable resorption profiles, thereby widening therapeutic options and improving safety margins. At the same time, mechanical occlusion technologies including vascular plugs and detachable coils are being refined to balance thrombogenicity with vessel preservation, enabling tailored solutions for diverse anatomic challenges.

Parallel improvements in microcatheter design and flow-directed delivery systems are lowering procedural complexity and increasing the precision of agent deployment. These technological gains are amplified by enhanced imaging modalities and intra-procedural guidance tools that together reduce device migration risk and improve occlusion completeness. In practice, clinicians are adopting multimodal strategies-combining devices and materials across platforms-to achieve durable outcomes in complex cases. Commercially, these technical evolutions are prompting value-based conversations with health systems that emphasize total cost of care, procedural throughput, and long-term clinical durability rather than device price alone. Consequently, manufacturers are recalibrating portfolio strategies to prioritize interoperability, training support, and evidence generation that demonstrate real-world clinical and economic benefits.

Comprehensive appraisal of how evolving trade policies are reshaping procurement, manufacturing decisions, and market access for embolization device stakeholders

Recent tariff measures originating from the United States have injected fresh complexity into global supply chains for medical devices, with cascading implications for manufacturers, distributors, and health systems. Tariffs alter the cost calculus of component sourcing and finished goods imports, which can prompt strategic shifts such as relocating assembly operations, qualifying alternative suppliers, or increasing vertical integration to preserve margin and supply continuity. For companies reliant on cross-border procurement of specialized polymers, metals, microcatheter components, and imaging-compatible markers, these policy changes can increase lead times as vendors reassess routing and inventory policies.

The cumulative operational impact extends beyond unit costs. Procurement teams are adjusting contract terms and inventory strategies to buffer against tariff volatility, while regulatory and quality functions must revalidate device configurations when manufacturing locations or component suppliers change. Clinicians and hospital purchasers may encounter altered pricing dynamics or phased product introductions as manufacturers prioritize allocations to markets with more favorable trade terms. Moreover, tariff-driven supply rebalancing can accelerate regionalization of manufacturing, encouraging companies to co-locate production nearer to end markets to reduce trade exposure. As a result, strategic planning now requires integrated scenario modeling across procurement, regulatory, and commercial teams to ensure uninterrupted access to critical embolization and occlusion technologies and to protect clinical continuity.

Actionable segmentation intelligence showing how product types, materials, and technologies interplay with clinical use cases and care settings to shape adoption

Deep segmentation analysis reveals distinct performance drivers and adoption barriers across product categories, materials, technologies, clinical applications, and care settings that determine strategic priorities for manufacturers and health systems. Within product types, embolization coils-available as detachable and pushable configurations-remain integral for targeted mechanical occlusion where placement precision is paramount, while liquid embolic agents, including ethylene vinyl alcohol copolymer and N-butyl cyanoacrylate formulations, provide conformable options for complex vascular beds. Microspheres and particulate embolic agents offer calibrated occlusion with predictable distal penetration, and vascular plugs deliver rapid proximal vessel occlusion for certain anatomies. Each product class carries unique handling characteristics, imaging visibility profiles, and operator learning curves that influence clinical pathway adoption.

Material selection further differentiates device performance, as biological agents often emphasize biocompatibility and resorption dynamics, while synthetic agents provide consistency and longer-term permanence. Technology modalities-flow-directed embolization, mechanical occlusion, and microcatheter delivery systems-interact with device choice to optimize procedural efficiency and outcome durability across indications. Clinical applications span hemorrhage control, hepatic embolization, neurovascular interventions, peripheral vascular occlusions, and uterine fibroid embolization, many of which place divergent demands on device flexibility, occlusion permanence, and embolic particle behavior. Finally, end user environments such as ambulatory surgical centers, hospitals, and specialty clinics influence purchasing protocols, inventory management, and training investments, with each setting requiring tailored product configurations and service models. Integrated segmentation insight therefore supports targeted product development, differentiated clinical training, and value propositions that align with specific procedural workflows and institutional procurement criteria.

Insightful regional perspectives highlighting how regulatory, reimbursement, and clinical adoption differences across major territories shape strategic market approaches

Regional dynamics exert a powerful influence on clinical practice patterns, reimbursement frameworks, and supply chain architectures, resulting in divergent priorities across major geographies. In the Americas, clinician demand often favors rapid procedural turnaround and outpatient-capable solutions, prompting emphasis on devices that facilitate efficient workflows and strong training support. Regulatory pathways and payer structures in this region pressure manufacturers to demonstrate both clinical efficacy and economic value, which in turn shapes evidence generation strategies and commercial messaging.

Across Europe, the Middle East & Africa, the market environment is fragmented by heterogeneous reimbursement policies, variable infrastructure, and diverse clinical guidelines. This creates opportunities for regionally adapted product portfolios and collaborative partnerships that address local training needs and procurement cycles. In Asia-Pacific, rapid investments in interventional capacity and emerging centers of excellence are expanding the clinical footprint for embolization therapies. Supply chain localization and strategic alliances with regional distributors are often prioritized to accelerate access, while product adaptations may be needed to match procedural preferences and device registration requirements. Ultimately, each region presents unique trade-offs between regulatory complexity, cost sensitivities, and clinical adoption velocities, requiring manufacturers to deploy differentiated market entry strategies and to invest in local evidence and training programs to achieve sustained uptake.

Examination of competitive dynamics and how product innovation, evidence generation, and channel strategies determine market positioning for device manufacturers

Competitive dynamics in the embolization and occlusion device arena are driven by a combination of product innovation, clinical evidence, service offerings, and channel relationships. Leading companies differentiate through targeted investments in next-generation materials, improved delivery profiles, and enhanced imaging compatibility, while also prioritizing clinician training and outcomes tracking. Partnerships between device manufacturers and academic centers or clinical networks are increasingly important for generating high-quality real-world evidence and building long-term credibility with interventional teams.

At the go-to-market level, distributors, strategic alliances, and direct sales models each offer distinct advantages depending on the therapeutic area and end user target. Companies that pair product innovation with comprehensive training curricula and robust post-market surveillance tend to foster stronger clinician loyalty and faster uptake. Moreover, firms that can demonstrate interoperability with existing catheter platforms and imaging systems reduce procedural friction and accelerate adoption. Competitive positioning also depends on the ability to navigate procurement preferences in hospitals and ambulatory centers, and to present clear value propositions that align with both clinical outcomes and operational efficiencies. Collectively, these factors create a landscape where nimble innovators and established incumbents must continually refine their offerings to sustain leadership.

Practical and prioritized recommendations for manufacturers to align product innovation, clinical evidence, and commercial execution to accelerate adoption

Industry leaders should pursue a coordinated set of actions that align product development, clinical evidence objectives, and commercial execution to capture long-term value in embolization therapies. Prioritize modular design and compatibility with commonly used microcatheter platforms to reduce procedural friction and to broaden clinical applicability across multiple indications. Invest in differentiated biomaterials and imaging markers that enhance delivery control and visualization; these technical distinctions can be translated into demonstrable clinical benefits through well-structured studies and registries.

Strengthen partnerships with clinical centers to co-develop training programs that accelerate operator proficiency and reduce variability in outcomes. Simultaneously, reassess supply chain footprints to mitigate exposure to tariff-driven disruptions and to ensure redundancy for critical components. Expand payer engagement to articulate total cost of care benefits, focusing on metrics such as procedural time, complication reduction, and downstream resource utilization. Finally, tailor commercial approaches to regional and facility-level nuances by offering flexible contracting, local evidence packages, and integrated post-sales support. By taking these integrated steps, companies can reduce adoption barriers, differentiate in competitive procurement environments, and demonstrate measurable improvements in both clinical and economic outcomes.

Transparent mixed-methods research approach combining clinical evidence review, expert interviews, and cross-validation to ensure robust actionable insights

This research synthesizes peer-reviewed clinical literature, device regulatory filings, guidance documents from health authorities, primary interviews with interventional clinicians and procurement leaders, and a structured review of manufacturer technical specifications to create a comprehensive understanding of embolization and occlusion device dynamics. Data collection emphasized reproducibility and source triangulation, combining qualitative insights from key opinion leaders with device performance characteristics extracted from publicly available regulatory submissions and physician-led registries. Interview subjects were selected to reflect a diversity of clinical specialties, practice settings, and geographic regions to capture the breadth of procedural preferences and adoption considerations.

Analytical methods included thematic coding of interview transcripts to identify recurring barriers and enablers, cross-comparison of device feature sets to assess technological differentiation, and scenario analysis to explore supply chain and policy-driven contingencies. All findings were validated through iterative expert review and reconciled against clinical guidelines and published safety reports. Where manufacturer-provided claims were considered, they were corroborated with independent clinical evidence and regulatory summaries to ensure balanced interpretation. The methodology intentionally avoided reliance on single-source commercial data, favoring mixed-methods synthesis to provide robust, actionable insights for R&D, clinical affairs, and commercial leadership.

Concluding synthesis emphasizing clinical, operational, and strategic imperatives that will determine which technologies achieve widespread adoption

Transcatheter embolization and occlusion devices occupy a strategic nexus of clinical need, materials innovation, and system-level economic considerations. The techniques and technologies that define this field are maturing in ways that expand clinical applicability while simultaneously increasing demands on manufacturers to deliver demonstrable value across diverse care settings. Successful commercialization will hinge on an ability to reconcile product performance with pragmatic deployment factors such as training, imaging compatibility, and supply chain resilience. Moreover, trade and policy shifts underscore the importance of agile manufacturing and procurement planning to sustain device availability in the face of external shocks.

For stakeholders across the ecosystem, the path forward is clear: invest in clinical partnerships to build high-quality evidence, prioritize modular and interoperable device designs to reduce procedural friction, and align commercial models with regional healthcare realities. By doing so, companies and health systems can accelerate safe adoption, improve patient outcomes, and enhance procedural efficiency. The collective focus on these priorities will determine which innovations translate into standard practice and which remain niche interventions, shaping the future of minimally invasive vascular care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transcatheter Embolization & Occlusion Device Market, by Product Type

  • 8.1. Embolization Coils
    • 8.1.1. Detachable Coils
    • 8.1.2. Pushable Coils
  • 8.2. Liquid Embolic Agents
    • 8.2.1. Ethylene Vinyl Alcohol Copolymer
    • 8.2.2. N-Butyl Cyanoacrylate
  • 8.3. Microspheres
  • 8.4. Particulate Embolic Agents
  • 8.5. Vascular Plugs

9. Transcatheter Embolization & Occlusion Device Market, by Material

  • 9.1. Biological Agents
  • 9.2. Synthetic Agents

10. Transcatheter Embolization & Occlusion Device Market, by Technology

  • 10.1. Flow Directed Embolization
  • 10.2. Mechanical Occlusion
  • 10.3. Microcatheter Delivery Systems

11. Transcatheter Embolization & Occlusion Device Market, by Application

  • 11.1. Hemorrhage Control
  • 11.2. Hepatic Embolization
  • 11.3. Neurovascular Embolization
  • 11.4. Peripheral Vascular Embolization
  • 11.5. Uterine Fibroid Embolization

12. Transcatheter Embolization & Occlusion Device Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Transcatheter Embolization & Occlusion Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Transcatheter Embolization & Occlusion Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Transcatheter Embolization & Occlusion Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Transcatheter Embolization & Occlusion Device Market

17. China Transcatheter Embolization & Occlusion Device Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AngioDynamics, Inc.
  • 18.6. B. Braun Melsungen AG
  • 18.7. Boston Scientific Corporation
  • 18.8. Cook Medical LLC
  • 18.9. Edwards Lifesciences Corporation
  • 18.10. Johnson & Johnson
  • 18.11. Medtronic plc
  • 18.12. Merit Medical Systems, Inc.
  • 18.13. Penumbra, Inc.
  • 18.14. Terumo Corporation
  • 18.15. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 153. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 154. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 176. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 177. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 178. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 184. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 185. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 186. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)